DR. DHRUBOJYOTI SARKER

Abstract

Aims- anti VEGF agents are routinely employed for managing diabetic macular edema(DME). We aim to evaluate the magnitude of the injection’s effect on the fellow un injected eye

Method-a cohort of bilateral DME cases who received unilateral bevacizumab(BCV) were retrospectively evaluated. Collected data included history, ophthalmic and systemic findings and OCT measurements for central macular thickness(CMT)

Results-the 23 patients who were included in this study. Followed up monthly, comparative analysis performed on 6th month visit on both eyes. Mean number of injections was 3.7. At the end of 6 months the mean CMT reduction was 73.16± 115 µm in injected eyes, while the value is 46± 89 µm in non-injected eyes.11 injected and 8 non injected eyes showed CMT reduction ≥50 micron. Visual acuity improved in 13 injected and 10 non injected eyes

Conclusion- unilateral BCV injections in patients with bilateral DME are often associated with contralateral anatomical and functional improvement

Full Text